Liquidia Just Paid $380 Million to End a Patent War That Crushed the StockTwo weeks ago, Liquidia Corporation (LQDA) got punched in the face by a Delaware patent ruling. The stock fell about 57% in a day. Wall Street treated the company like a biotech that might lose its main product story. Law firms started fishing for securities claims. The whole name became a lawsuit ticker. Then Tuesday after the close, Liquidia and United Therapeutics Corp. (UTHR) ended the fight. ## The Settlement That Stops The Bleeding The companies announced a global settlement covering all six pending lawsuits between them. Net payments total about $380.7 million. Liquidia pays $175 million within 30 business days, then two more $72.7 million checks due by January 31 and April 30, 2027, plus about $60.3 million to other parties this month. In return, YUTREPIA, Liquidia's inhaled treprostinil powder for pulmonary arterial hypertension, keeps commercializing for PAH without that stack of cases hanging over the next few years. That is the whole point of the deal. Not a cute legal footnote. A path to sell the drug without every quarter turning into another courtroom calendar. Liquidia also agreed not to appeal the parts of the September 30 ruling that upheld two patent claims tied to PH-ILD, a related lung disease indication. It is pulling PH-ILD off the label and stopping promotion there. The company is choosing PAH certainty over a wider label fight it just lost. After-hours, the stock ripped roughly 40% as traders priced the cloud lifting. Regular-session closes still sat in the high $20s after the September crash. The settlement is the first clean read on what the business looks like when the legal fog thins. ## What The Cash Balance Actually Buys This only works if Liquidia can write the checks without blowing up the franchise. Preliminary, unaudited third-quarter YUTREPIA net product sales were about $222.7 million. Cash and equivalents sat near $396.1 million at September 30. Management says ongoing product sales plus that cash pile fund the settlement. No new financing announced with the deal. That matters. A settlement that forces a dilutive raise would have traded like a second punch. A settlement funded by product cash trades like a tax paid to keep the commercial engine running. United Therapeutics still owns the bigger treprostinil franchise and the patents that hurt Liquidia on PH-ILD. Liquidia keeps a commercial PAH product and a cleared legal path. Both sides stop burning legal spend on a multi-case war. ## The Risk That Did Not Disappear Paying $380 million does not make YUTREPIA a risk-free annuity. PAH is still a competitive specialty market. Label limits now exclude the PH-ILD path the court closed. Reimbursement, physician adoption, and manufacturing still sit on the operating side of the ledger. And after a 57% crash followed by a violent after-hours bounce, the stock can swing on any whisper about sales pace or cash burn. There is also the simple math of the checks. $175 million leaves soon. Two more large installments land in early 2027. Investors will watch whether product cash really covers the schedule without a balance-sheet surprise. For a name that spent September looking like a patent casualty, the new story is simpler and colder. The courtroom war is over. The commercial clock is back on. ## Bottom Line Liquidia just bought legal peace with United Therapeutics for about $380.7 million so YUTREPIA can keep selling into PAH without six open cases. The September patent crash was the scare. The settlement is the reset. The next fight is pure commercial execution, not another Delaware docket.